Implantable Continuous Glucose Monitors (I-CGM)

Medicare covers FDA-approved therapeutic implantable continuous glucose monitors for beneficiaries with diabetes mellitus when the treating practitioner documents training (via a prescription/order), the device is used per FDA indications, and the beneficiary is either insulin-treated or has documented problematic hypoglycemia. Continued coverage requires an in-person or Medicare-approved telehealth visit every 6 months to document adherence and the treatment plan; short-term diagnostic I-CGM use (72 hours to 1 week) and non–FDA-approved/non-therapeutic devices are not covered.

"The beneficiary has a diagnosis of diabetes mellitus."

Sign up to see full coverage criteria, indications, and limitations.